Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study

The use of modulator drugs that target the Cystic Fibrosis transmembrane conductance regulator (CFTR) is the final frontier in the treatment of Cystic Fibrosis (CF), a genetic multiorgan disease. F508del is the most common mutation causing defective formation and function of CFTR. Elexacaftor-tezaca...

Descripción completa

Detalles Bibliográficos
Autores principales: Migliorisi, Giuseppe, Collura, Mirella, Ficili, Francesca, Pensabene, Tiziana, Bongiorno, Dafne, Collura, Antonina, Di Bernardo, Francesca, Stefani, Stefania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145356/
https://www.ncbi.nlm.nih.gov/pubmed/35631432
http://dx.doi.org/10.3390/ph15050606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145356/
https://www.ncbi.nlm.nih.gov/pubmed/35631432
http://dx.doi.org/10.3390/ph15050606

Ejemplares similares